These comments are preliminary and based on early data from the use of SDMA in veterinary patients. Consider treatment recommendations listed under IRIS CKD Stage 4 for this patient. In IRIS CKD Stage 3 patients with low body condition scores, SDMA ≥45 µg/dl may indicate the degree of renal dysfunction has been underestimated. Consider treatment recommendations listed under IRIS CKD Stage 3 for this patient. In IRIS CKD Stage 2 patients with low body condition scores, SDMA ≥25 µg/dl may indicate the degree of renal dysfunction has been underestimated. A persistent increase in SDMA above 14 µg/dl suggests reduced renal function and may be a reason to consider a dog or cat with creatinine values <1.4 or <1.6 mg/dl, respectively, as IRIS CKD Stage 1. SDMA concentrations in blood (plasma or serum) may be a more sensitive biomarker of renal function than blood creatinine concentrations. Interpreting Blood Concentrations of Symmetric Dimethylarginine (SDMA) in CKD This parallels the IRIS consensus statement on standard treatment for glomerulonephritis ( J Vet Intern Med 2013 27:S27–S43). We recommend that IRIS CKD Stage 1 patients with persistent proteinuria (UPC ≥ 0.5 for dogs or 0.4 for cats) are not only monitored and thoroughly investigated but also receive standard treatment for proteinuria as currently recommended for IRIS CKD Stages 2 to 4. We recommend replacement of the existing abbreviations for blood pressure substages (AP0-AP1) with descriptive terms as follows: Systolic blood pressure (mm Hg)

The full version of 2015 Guidelines will be uploaded during our website relaunch by the end of 2015. A summary of these new recommendations is presented here. The IRIS Board made three significant changes to CKD Guidelines during 20.

Blood pressure stages chart pdf